The Advisory Board Company Stock Rating Upgraded by Zacks (ABCO)
The Advisory Board Company (NASDAQ:ABCO) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research note issued to investors on Wednesday. The firm currently has a $52.50 price target on the stock. Zacks‘s price objective indicates a potential upside of 0.54% from the company’s current price.
In other The Advisory Board Company news, President David L. Felsenthal sold 4,272 shares of the stock on the open market in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $52.14, for a total transaction of $222,742.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of The Advisory Board Company (NASDAQ:ABCO) traded up 1.50% during mid-day trading on Wednesday, hitting $52.22. The stock had a trading volume of 182,024 shares. The Advisory Board Company has a one year low of $46.58 and a one year high of $70.55. The stock’s 50-day moving average is $50.42 and its 200-day moving average is $58.67. The company has a market cap of $1.911 billion and a price-to-earnings ratio of 76.79.
The Advisory Board Company (NASDAQ:ABCO) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.04. The company had revenue of $138.00 million for the quarter, compared to the consensus estimate of $137.01 million. During the same quarter in the previous year, the company posted $0.33 earnings per share. The company’s revenue for the quarter was up 15.3% on a year-over-year basis. On average, analysts predict that The Advisory Board Company will post $1.26 earnings per share for the current fiscal year.
A number of other firms have also recently commented on ABCO. Analysts at Raymond James reiterated an “outperform” rating on shares of The Advisory Board Company in a research note on Friday, May 9th. They now have a $57.00 price target on the stock, down previously from $68.00. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $66.07.
The Advisory Board Companyprovides best practices research and analysis, software tools, and management and advisory services to the health care and education industries.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.